Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 27 Fallopian Tube Neoplasms 9 Prostatic Neoplasms 8 Breast Neoplasms 8 Neoplasms 6 Pancreatic Neoplasms 5 Endometrial Neoplasms 5 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Melanoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1

Interventions

Cyclophosphamide 241 Rituximab 223 Etoposide 138 Filgrastim 113 Vincristine 112 Doxorubicin 104 Prednisone 90 Cytarabine 90 Methotrexate 79 fludarabine phosphate 77 Radiotherapy 76 Peripheral Blood Stem Cell Transplantation 71 Melphalan 71 Busulfan 60 Tacrolimus 48 Dexamethasone 48 Mycophenolic Acid 46 Carmustine 46 Granulocyte Colony-Stimulating Factor 44 fludarabine 43 Antilymphocyte Serum 40 Ifosfamide 38 sargramostim 34 Whole-Body Irradiation 34 Cyclosporine 33 Bortezomib 32 Gemcitabine 30 Methylprednisolone 27 Bendamustine Hydrochloride 27 Lenalidomide 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × niraparib × Clear all

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡